thalidomide has been researched along with Idiopathic Pulmonary Fibrosis in 9 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Idiopathic Pulmonary Fibrosis: A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the efficacy of thalidomide in suppressing cough in patients with IPF." | 9.16 | Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. ( Danoff, SK; Horton, KM; Horton, MR; Lechtzin, N; Liu, MC; Mathew, L; Polito, AJ; Santopietro, V, 2012) |
| "The "Thalidomide tragedy" is a landmark in the history of the pharmaceutical industry." | 7.01 | Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis. ( Alampady, V; Baby, K; Byregowda, BH; Dsouza, NN; Maity, S; Nayak, Y, 2023) |
| "Thalidomide is an infamous drug whose use by pregnant women in the middle of last century tragically resulted in serious birth defects." | 6.48 | Revisiting thalidomide: fighting with caution against idiopathic pulmonary fibrosis. ( Hallowell, RW; Horton, MR, 2012) |
| "Thalidomide is a powerful treatment for inflammatory and cancer-based diseases." | 6.47 | Apoptosis induction by thalidomide: critical for limb teratogenicity but therapeutic potential in idiopathic pulmonary fibrosis? ( Jungck, D; Knobloch, J; Koch, A, 2011) |
| "The CQLQ was administered as an outcome within a previously published 27-week, placebo-controlled, crossover trial of thalidomide for cough in IPF." | 5.17 | Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis. ( Hilliard, ME; Horton, MR; Lechtzin, N, 2013) |
| "To determine the efficacy of thalidomide in suppressing cough in patients with IPF." | 5.16 | Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. ( Danoff, SK; Horton, KM; Horton, MR; Lechtzin, N; Liu, MC; Mathew, L; Polito, AJ; Santopietro, V, 2012) |
| "The "Thalidomide tragedy" is a landmark in the history of the pharmaceutical industry." | 3.01 | Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis. ( Alampady, V; Baby, K; Byregowda, BH; Dsouza, NN; Maity, S; Nayak, Y, 2023) |
| "Few clinical trials have focused on treatments for IPF cough." | 2.55 | Etiology and treatment of cough in idiopathic pulmonary fibrosis. ( Horton, MR; Hughes, AH; Vigeland, CL, 2017) |
| "Thalidomide is an infamous drug whose use by pregnant women in the middle of last century tragically resulted in serious birth defects." | 2.48 | Revisiting thalidomide: fighting with caution against idiopathic pulmonary fibrosis. ( Hallowell, RW; Horton, MR, 2012) |
| "Thalidomide is a powerful treatment for inflammatory and cancer-based diseases." | 2.47 | Apoptosis induction by thalidomide: critical for limb teratogenicity but therapeutic potential in idiopathic pulmonary fibrosis? ( Jungck, D; Knobloch, J; Koch, A, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Dsouza, NN | 1 |
| Alampady, V | 1 |
| Baby, K | 1 |
| Maity, S | 1 |
| Byregowda, BH | 1 |
| Nayak, Y | 1 |
| Lechtzin, N | 3 |
| Hilliard, ME | 1 |
| Horton, MR | 5 |
| Swigris, JJ | 1 |
| Brown, KK | 1 |
| Belkin, A | 1 |
| Vigeland, CL | 1 |
| Hughes, AH | 1 |
| Knobloch, J | 1 |
| Jungck, D | 1 |
| Koch, A | 1 |
| Santopietro, V | 1 |
| Mathew, L | 1 |
| Horton, KM | 1 |
| Polito, AJ | 1 |
| Liu, MC | 1 |
| Danoff, SK | 1 |
| Hallowell, RW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide[NCT00600028] | Phase 3 | 25 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary endpoint, suppression of cough was measured by the Cough Quality of Life Questionnaire (CQLQ) to measure the effect of interventions on cough-specific quality of life.~CQLQ consist of 28 questions about cough and its effects using Likert-like 4-point scales, with lower scores indicating less effect of cough on health related quality of life.~CQLQ scale ranges from 28 to 112 ( The lower the value, the higher the quality of life, 28 is considered the best)." (NCT00600028)
Timeframe: 6 months
| Intervention | units on a scale (Mean) |
|---|---|
| Arm Thalidomide 1st, Placebo 2nd (Intervention Thalidomide) | 47.3 |
| Arm Thalidomide 1st, Placebo 2nd (Intervention Placebo) | 55.2 |
| Arm Placebo 1st, Thalidomide 2nd (Intervention Placebo) | 61.6 |
| Arm Placebo 1st, Thalidomide 2nd (Intervention Thalidomide) | 44.5 |
"The secondary endpoint, suppression of cough was measured by the visual analog scale of cough (VAS) was significantly lower during treatment with thalidomide than placebo.~Secondary endpoints were Cough VAS - the visual analog scale of cough evaluates the severity of cough in patients with IPF.~Visual analog scale of cough ranges from 0 to 100 (0 is considered the best).~St. George Respiratory Questionnaire helps to evaluate cough-specific and respiratory quality of life in patients with IPF.~St. George Respiratory Questionnaire score ranges from 0 to 100 (0 is considered the best)." (NCT00600028)
Timeframe: 6 months
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Severity of cough (VAS Score) | Quality of life (SGRQ Score) | |
| Arm Placebo 1st, Thalidomide 2nd (Intervention Placebo) | 68 | 58.8 |
| Arm Placebo 1st, Thalidomide 2nd (Intervention Thalidomide) | 17.8 | 40.7 |
| Arm Thalidomide 1st, Placebo 2nd (Intervention Placebo) | 65.9 | 54.7 |
| Arm Thalidomide 1st, Placebo 2nd (Intervention Thalidomide) | 30.3 | 46.4 |
4 reviews available for thalidomide and Idiopathic Pulmonary Fibrosis
| Article | Year |
|---|---|
Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis.
Topics: COVID-19; Humans; Idiopathic Pulmonary Fibrosis; Inflammation; Lung; Pandemics; Thalidomide; Transfo | 2023 |
Etiology and treatment of cough in idiopathic pulmonary fibrosis.
Topics: Antitussive Agents; Comorbidity; Cough; Gastroesophageal Reflux; Humans; Idiopathic Pulmonary Fibros | 2017 |
Apoptosis induction by thalidomide: critical for limb teratogenicity but therapeutic potential in idiopathic pulmonary fibrosis?
Topics: Animals; Apoptosis; Disease Models, Animal; Extremities; Idiopathic Pulmonary Fibrosis; Limb Deformi | 2011 |
Revisiting thalidomide: fighting with caution against idiopathic pulmonary fibrosis.
Topics: Humans; Idiopathic Pulmonary Fibrosis; Thalidomide | 2012 |
2 trials available for thalidomide and Idiopathic Pulmonary Fibrosis
| Article | Year |
|---|---|
Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis.
Topics: Aged; Chronic Disease; Cough; Cross-Over Studies; Disease Progression; Double-Blind Method; Female; | 2013 |
Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial.
Topics: Aged; Antitussive Agents; Constipation; Cough; Dizziness; Double-Blind Method; Female; Humans; Idiop | 2012 |
3 other studies available for thalidomide and Idiopathic Pulmonary Fibrosis
| Article | Year |
|---|---|
Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis.
Topics: Antitussive Agents; Cough; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Thalidomide | 2013 |
Author reply: To PMID 22986377.
Topics: Antitussive Agents; Cough; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; Thalidomide | 2013 |
Summaries for patients. Thalidomide treatment for cough in patients with idiopathic pulmonary fibrosis.
Topics: Aged; Antitussive Agents; Constipation; Cough; Female; Humans; Idiopathic Pulmonary Fibrosis; Male; | 2012 |